Member Info for Sangijuelas1

What do you mean?

That's 20 minutes of my life I won't get back from someone posting crap that they don't understand.

The US filing is an amendment to the original registration of 4D Pharma Ordinary Shares on Nasdaq.

The amendment just adds the recent Annual Report to the original prospectus.

So basically a repeat of last years filing but wit an amendment.

Are you on the wrong board?

I don't think you should be giving financial advice Phil

Porky are you saying the statement in the annual report about the restrictive covenant on the loan is wrong and you are right?

What do you need to trust?

There are facts. From the annual report. They say they have cash to September.

They need $45m

5 options
1) Manage raise cash from outlicensing Blautix or get vax milestone
2) Raise $45m on Nasdaq. Tricky when Mcap just over $100m
3)Massively cut costs/staff and try muddle through with much smaller raise, access some Oxford cash
4) Run out of cash, wind down
5) Get bought out

So could be good, could be bad, who knows?

And 4D announced the loan in July with the fundraise condition as part of it.

A few weeks later the bear market started and so they likely couldn't raise and then Oliveira picked up the pace of the sells.

4D Good company but screwed by the market

See the 19th August RNS where SO reduced. Shortly after the loan announcement. He probably had access to the terms and knew a raise was planned

Forte blew up 3 weeks after that.

Porky why did they say they had accessed $12.5m but it was only $5m?

If they have only been given 5 to spend so far and have to keep 7.5 in the bank, what makes you think Oxford will offer up more?

The whole loan was just cover for a raise that never happened.

And Phil, Oliveira was selling out before Forte. He just picked up the pace when they collapsed

I believed the company was more financially secure than it was as they stated they had a loan for a certain amount which turned out to be less.

When it was obvious cash raise harder because of bear market thought had another potential $17.5m available from Oxford.

Now much less likely as the whole thing was probably cover for a raise that couldn't go ahead because of the depressed SP.

Maybe that's why Oliveira walked

Well when you are burning £2m a month it kind of matters.

In case you hadn't noticed there is a biotech bear market making it tougher to raise capital.

The hope had been the Oxford option but that doesn't seem very realistic given what we now know about the loan.

Phil I will explain again. I had high expectations but that was tempered by the fact that their claim to have received $12.5m from Oxford to fund business turned out to be only $5m.

Thereby wiping out about 3-4 months funding.

Either way, looking at it neutrally, a few weeks back we had a couple of weeks where the price seemed to freeze between 36-40 despite relatively high volume.

Then there was the mini breakout with higher volatility and now it seems to have seized up a bit. Volume lower today so maybe that.

Any ideas?

Oxford have only delivered $5m so can't see that happening.
Merck are not going to buy more on the open market. They haven't in 3 years so why would they do that now.
What are you expecting from the FDA on Blautix?
We were told in September 2020 they were going to look for a Blautix partner. Still nothing so unlikely next week.
What the **** is a TR1 going to do?

Face it Porky, you want Number Go Up so you can offload to the next mug punter. And move on to your next pump and dump.

How are SNG doing now?

Bit tricky to do that when no results are due

Just seem like a run of the mill pumper dumper to me.

We've attracted quite a few over the last couple of years

Ramping is where you focus only on the positive and forget to mention things like the company is running low on cash and needs to find some soon.

So, there are many positives but you can't just ignore the uncertainties.

Taunton Boy it seems you literally created an account on April Fools Day with the sole intention of pumping this stock.